{"id":"W4324136592","doi":"10.1200/jco.2023.41.6_suppl.tps750","title":"Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Population Health Research Institute; McMaster University Medical Centre; St. Joseph’s Healthcare Hamilton; Ottawa Hospital; Health Sciences Centre; Ontario Clinical Oncology Group; Grand River Hospital; McMaster University; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Renal cell carcinoma; Sunitinib; Kidney cancer; Internal medicine; Oncology; Nephrectomy; Immunotherapy; Urology; Cancer; Kidney","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001563858,0.001538556,0.001297956,0.0004346413,0.0004191837,0.00112859,0.001174364,0.001667736,0.00684629],"category_scores_gemma":[0.001006869,0.0005322372,0.001157605,0.0003378667,0.0009453461,0.0008437346,0.0004683633,0.00301346,0.001259202],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001354008,"about_ca_system_score_gemma":0.001825932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001350536,"about_ca_topic_score_gemma":0.002499597,"domain_scores_codex":[0.9995766,0.0001744778,0.00001630404,0.0001027088,0.00004310521,0.0000867213],"domain_scores_gemma":[0.9993318,0.00008257331,0.0001340517,0.00005630077,0.00003827935,0.000357014],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8468766,0.04843117,0.002899993,0.00086159,0.001498213,0.000223828,0.0001901631,0.002287933,0.01665438,0.0006211324,0.006099563,0.07335557],"study_design_scores_gemma":[0.8145904,0.1771,0.003017588,0.00003568503,0.0002979627,0.0001469608,0.0000342961,0.0008612071,0.001233387,0.0003195511,0.002344681,0.00001831827],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9765427,0.002937834,0.001320474,0.001427046,0.0005511678,0.009274385,0.002345324,0.0002580737,0.005342904],"genre_scores_gemma":[0.97703,0.00164653,0.002679637,0.002271462,0.0002810345,0.007423005,0.00355813,0.00004964354,0.005060517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00684629,"threshold_uncertainty_score":0.02290308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1758098658183557,"score_gpt":0.4993469792111426,"score_spread":0.3235371133927869,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}